Institutional Ownership
Kalaris Therapeutics Inc
CUSIP 482929106COMKLRSQ1 2026
13D / 13G Filings
7
Schedule 13D/13G on record
Beneficial Filers
5
Distinct reporting persons
Largest Stake
61.2%
Max % of class reported
Institutional Holders
55
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
7 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Samsara Biocapital, L.P. | 13D/A | 56.5% | — | SEC |
| 2 | Feb 17, 2026 | Rtw Investments, LP | 13G | 5.7% | 1.30M | SEC |
| 3 | Dec 22, 2025 | Samsara Biocapital, L.P. | 13D/A | 56.5% | — | SEC |
| 4 | Jul 29, 2025 | Invus Public Equities, L.P. | 13G/A | 1.5% | 282.6K | SEC |
| 5 | May 15, 2025 | Ecor1 Capital, LLC | 13G/A | 1.1% | — | SEC |
| 6 | Mar 25, 2025 | Samsara Biocapital, L.P. | 13D | 61.2% | — | SEC |
| 7 | Mar 20, 2025 | Gilead Sciences, Inc. | 13G/A | 3.9% | 723.3K | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Samsara Biocapital, LLC | 12.95M | $74.71M |
| 2 | Rtw Investments, LP | 1.30M | $7.50M |
| 3 | Paradigm Biocapital Advisors LP | 700.0K | $4.04M |
| 4 | Alyeska Investment Group, L.P. | 572.7K | $3.27M |
| 5 | Siren, L.L.C. | 435.8K | $2.51M |
| 6 | Ikarian Capital, LLC | 360.0K | $2.08M |
| 7 | Propel Bio Management, LLC | 295.8K | $1.72M |
| 8 | Kalehua Capital Management LLC | 135.6K | $782.3K |
| 9 | Raymond James Financial Inc | 118.9K | $686.0K |
| 10 | Goldman Sachs Group Inc | 110.5K | $637.6K |